Rapport Therapeutics (RAPP) investor relations material

Opening remarks and agenda

• The meeting was called to order by the CEO, with legal counsel recording the minutes and confirmation that the meeting was held in accordance with bylaws and Delaware law.

• Stockholders were welcomed, and the agenda was limited to official business as described in the notice and proxy statement.

• Directors, executive team, and representatives from the audit firm and legal counsel were introduced.

• Rules of conduct and voting eligibility were explained, with instructions for submitting questions and voting through the virtual platform.

Board and executive committee updates

• Three nominees for Class 2 directors were presented for election to serve a three-year term, with no additional nominations received.

• The board unanimously recommended voting in favor of the director nominees.

Corporate governance

• An independent inspector of elections was appointed to oversee and tabulate voting results.

• The audit committee, composed entirely of independent directors, appointed the audit firm for the coming fiscal year.

• Stockholder ratification of the audit firm was sought as a matter of good governance, though not required by bylaws.